Stay updated on Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision tag updated to v3.4.3, replacing the previous v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-11T17:14:11.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added; the notice about lapse in government funding and the Revision: v3.4.1 entry were removed.
    Difference
    0.4%
    Check dated 2026-02-11T05:43:32.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    A site-wide notice about a lapse in government funding and potential data delays was added. The site revision was updated from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T05:21:22.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added a glossary display, introduced a new 'Last Update Submitted that Met QC Criteria' label, and updated the capitalization to 'No FEAR Act Data'. Updated the revision reference from v3.3.4 to v3.4.0.
    Difference
    0.2%
    Check dated 2026-01-28T03:24:18.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Revision: v3.3.4 update shows no substantive changes to the study details, eligibility criteria, locations, or contacts. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T01:29:20.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    District of Columbia was added to the Locations section. The District of Columbia Locations entry and HHS Vulnerability Disclosure were removed, and the page revision updated to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T17:21:11.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.